Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.87 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.87 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.87 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.87 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.87 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.87 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.87 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zaleplon SCHEMBL27637735 | 0.93 | KDM4E (0.96) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL29118 | 0.93 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL5605771 | 0.93 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL29375436 | 0.93 | KDM4E (1.00) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL3168939 | 0.92 | KDM4E (0.84) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4727312 | 0.92 | KDM4E (0.98) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726630 | 0.92 | KDM4E (0.98) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726073 | 0.90 | KDM4E (0.93) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| SCHEMBL5811647 | 0.90 | KDM4E (0.80) | KDM4EMAPK1GABRA1GABRG2GABRB3 | |
| Zaleplon SCHEMBL4726658 | 0.90 | KDM4E (0.93) | KDM4EMAPK1GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | claimed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | claimed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | claimed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | claimed |
| US-4626538-A | [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1986-12-02 | — | — | US | claimed |
| EP-1713808-B1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7498434-B2 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC (US) | 2009-03-03 | — | — | US | disclosed |
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | MALLINCKRODT INC, (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1713808-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT, INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070931-A1 | TWO-PHASE METHOD FOR THE SYNTHESIS OF SELECTED PYRAZOLOPYRIMIDINES | MALLINCKRODT INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-0208846-A1 | [7-(3-Disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1987-01-21 | — | — | EP | disclosed |
| US-4626538-A | [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines | AMERICAN CYANAMID COMPANY (US) | 1986-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155995-A1 | Two-phase method for the synthesis of selected pyrazolopyrimidines | AZI2, CDK2, TPMT | KDM4E 3705/4885MAPK1 558/4885GABRA1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.